N Jewel Samadder1,2,3, Douglas Riegert-Johnson2,3,4, Lisa Boardman5, Deborah Rhodes6,7, Myra Wick2,3,8, Scott Okuno9, Katie L Kunze10, Michael Golafshar10, Pedro L S Uson11, Luke Mountjoy11, Natalie Ertz-Archambault11, Neej Patel1, Eduardo A Rodriguez1, Blanca Lizaola-Mayo1, Michael Lehrer12, Cameron S Thorpe13, Nathan Y Yu13, Edward D Esplin14, Robert L Nussbaum14, Richard R Sharp3,15, Cindy Azevedo3, Margaret Klint2, Megan Hager2, Sarah Macklin-Mantia2, Alan H Bryce11, Tanios S Bekaii-Saab11, Aleksandar Sekulic3,12, A Keith Stewart3,11. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Phoenix, Arizona. 2. Department of Clinical Genomics, Mayo Clinic, Phoenix, Arizona. 3. Center for Individualized Medicine, Mayo Clinic, Phoenix, Arizona. 4. Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic Florida, Jacksonville. 5. Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, New York. 6. Department of Medicine, Yale New Haven Hospital, New Haven, Connecticut. 7. Formerly with Division of General Internal Medicine, Department of Medicine, Mayo Clinic Rochester, New York. 8. Department of Obstetrics and Gynecology, Mayo Clinic Rochester, Rochester, Minnesota. 9. Department of Hematology and Oncology, Mayo Clinic Health System, Eau Claire, Wisconsin. 10. Department of Health Sciences Research, Mayo Clinic Arizona, Phoenix. 11. Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix. 12. Department of Dermatology, Mayo Clinic Arizona, Phoenix. 13. Department of Radiation Oncology, Mayo Clinic Arizona, Phoenix. 14. Invitae, San Francisco, California. 15. Department of Bioethics, Mayo Clinic, Rochester, Minnesota.
Abstract
IMPORTANCE: Hereditary factors play a key role in the risk of developing several cancers. Identification of a germline predisposition can have important implications for treatment decisions, risk-reducing interventions, cancer screening, and germline testing. OBJECTIVE: To examine the prevalence of pathogenic germline variants (PGVs) in patients with cancer using a universal testing approach compared with targeted testing based on clinical guidelines and the uptake of cascade family variant testing (FVT). DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter cohort study assessed germline genetic alterations among patients with solid tumor cancer receiving care at Mayo Clinic cancer centers and a community practice between April 1, 2018, and March 31, 2020. Patients were not selected based on cancer type, disease stage, family history of cancer, ethnicity, or age. EXPOSURES: Germline sequencing using a greater than 80-gene next-generation sequencing platform. MAIN OUTCOMES AND MEASURES: Proportion of PGVs detected with a universal strategy compared with a guideline-directed approach and uptake of cascade FVT in families. RESULTS: A total of 2984 patients (mean [SD] age, 61.4 [12.2] years; 1582 [53.0%] male) were studied. Pathogenic germline variants were found in 397 patients (13.3%), including 282 moderate- and high-penetrance cancer susceptibility genes. Variants of uncertain significance were found in 1415 patients (47.4%). A total of 192 patients (6.4%) had incremental clinically actionable findings that would not have been detected by phenotype or family history-based testing criteria. Of those with a high-penetrance PGV, 42 patients (28.2%) had modifications in their treatment based on the finding. Only younger age of diagnosis was associated with presence of PGV. Only 70 patients (17.6%) with PGVs had family members undergoing no-cost cascade FVT. CONCLUSIONS AND RELEVANCE: This prospective, multicenter cohort study found that universal multigene panel testing among patients with solid tumor cancer was associated with an increased detection of heritable variants over the predicted yield of targeted testing based on guidelines. Nearly 30% of patients with high-penetrance variants had modifications in their treatment. Uptake of cascade FVT was low despite being offered at no cost.
IMPORTANCE: Hereditary factors play a key role in the risk of developing several cancers. Identification of a germline predisposition can have important implications for treatment decisions, risk-reducing interventions, cancer screening, and germline testing. OBJECTIVE: To examine the prevalence of pathogenic germline variants (PGVs) in patients with cancer using a universal testing approach compared with targeted testing based on clinical guidelines and the uptake of cascade family variant testing (FVT). DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter cohort study assessed germline genetic alterations among patients with solid tumor cancer receiving care at Mayo Clinic cancer centers and a community practice between April 1, 2018, and March 31, 2020. Patients were not selected based on cancer type, disease stage, family history of cancer, ethnicity, or age. EXPOSURES: Germline sequencing using a greater than 80-gene next-generation sequencing platform. MAIN OUTCOMES AND MEASURES: Proportion of PGVs detected with a universal strategy compared with a guideline-directed approach and uptake of cascade FVT in families. RESULTS: A total of 2984 patients (mean [SD] age, 61.4 [12.2] years; 1582 [53.0%] male) were studied. Pathogenic germline variants were found in 397 patients (13.3%), including 282 moderate- and high-penetrance cancer susceptibility genes. Variants of uncertain significance were found in 1415 patients (47.4%). A total of 192 patients (6.4%) had incremental clinically actionable findings that would not have been detected by phenotype or family history-based testing criteria. Of those with a high-penetrance PGV, 42 patients (28.2%) had modifications in their treatment based on the finding. Only younger age of diagnosis was associated with presence of PGV. Only 70 patients (17.6%) with PGVs had family members undergoing no-cost cascade FVT. CONCLUSIONS AND RELEVANCE: This prospective, multicenter cohort study found that universal multigene panel testing among patients with solid tumor cancer was associated with an increased detection of heritable variants over the predicted yield of targeted testing based on guidelines. Nearly 30% of patients with high-penetrance variants had modifications in their treatment. Uptake of cascade FVT was low despite being offered at no cost.
Authors: Dai Geyang; Chen Gaowen; L I Xiaoxuan; Zheng Youhong; Wang Yuan; Li Xingsong; L I Jing; Zhou Jing; Xie Yu; Wang Yifeng Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2021-01-30
Authors: Pat W Whitworth; Peter D Beitsch; Rakesh Patel; Barry Rosen; Gia Compagnoni; Paul L Baron; Rache Simmons; Eric A Brown; Linsey Gold; Dennis Holmes; Linda Ann Smith; Michael Kinney; Ian Grady; Patricia Clark; Karen Barbosa; Samuel Lyons; Lee Riley; Cynara Coomer; Lisa Curcio; Antonio Ruiz; Sadia Khan; Heather MacDonald; Kevin Hughes; Mary Kay Hardwick; Brandie Heald; Sandra B Munro; Sarah M Nielsen; Edward D Esplin Journal: JAMA Netw Open Date: 2022-09-01
Authors: Yael Laitman; Sarah M Nielsen; Rinat Bernstein-Molho; Brandie Heald; Kathryn E Hatchell; Edward D Esplin; Eitan Friedman Journal: Breast Cancer Res Treat Date: 2022-09-12 Impact factor: 4.624
Authors: Rachel Pearlman; Wendy L Frankel; Benjamin J Swanson; Dan Jones; Weiqiang Zhao; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Christopher Bigley; Lori Nelsen; Paul J Goodfellow; Richard M Goldberg; Electra Paskett; Peter G Shields; Jo L Freudenheim; Peter P Stanich; Ilene Lattimer; Mark Arnold; Thomas W Prior; Mitchell Haut; Matthew F Kalady; Brandie Heald; Ian Paquette; David J Draper; Joanna M Brell; Sameer Mahesh; Kisa Weeman; Shyamal Bastola; Jeffrey Zangmeister; Aruna Gowda; Filix Kencana; Albert Malcolm; Yinong Liu; Sharon Cole; Charles Bane; Chaoyang Li; Esther Rehmus; Colin C Pritchard; Brian H Shirts; Angela Jacobson; Shelly A Cummings; Albert de la Chapelle; Heather Hampel Journal: JCO Precis Oncol Date: 2021-05-05
Authors: Angela R Solano; Pablo G Mele; Fernanda S Jalil; Natalia C Liria; Ernesto J Podesta; Leandro G Gutiérrez Journal: Cancers (Basel) Date: 2021-05-31 Impact factor: 6.639
Authors: Anna DiNucci; Nora B Henrikson; M Cabell Jonas; Sundeep Basra; Paula Blasi; Jennifer Brown; Edward D Esplin; Dina Hassen; Jing Hao; Yirui Hu; Tracey Klinger; Ilene Ladd; Kathleen Leppig; Meredith Lewis; Michelle Meyer; Steven Ney; Arvind Ramaprasan; Katrina Romagnoli; Zachary Salvati; Aaron Scrol; Rachel Schwiter; Leigh Sheridan; Brinda Somasundaram; Pim Suwannarat; Jennifer K Wagner; Alanna K Rahm Journal: J Pers Med Date: 2021-06-11
Authors: Anya Mezina; Neil Philips; Zoe Bogus; Noam Erez; Rui Xiao; Ruoming Fan; Kim M Olthoff; K Rajender Reddy; N Jewel Samadder; Sarah M Nielsen; Kathryn E Hatchell; Edward D Esplin; Anil K Rustgi; Bryson W Katona; Maarouf A Hoteit; Katherine L Nathanson; Kirk J Wangensteen Journal: JCO Precis Oncol Date: 2021-06-10